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Summary 
Spinal muscular atrophy (SMA) is a common fatal au- 
tosomal recessive disorder characterized by degener- 
ation of lower motor neurons, leading to progressive 
paralysis with muscular atrophy. The gene for SMA has 
been mapped to chromosome 5q13, where large-scale 
deletions have been reported. We describe here the 
inverted duplication of a 500 kb element in normal 
chromosomes and narrow the critical region to 140 kb 
within the telomeric region. This interval contains a 
20 kb gene encoding a novel protein of 294 amino 
acids. An highly homologous gene is present in the 
centromeric element of 95% of controls. The telomeric 
gene is either lacking or interrupted in 226 of 229 pa- 
tients, and patients retaining this gene (3 of 229) carry 
either a point mutation (Y272C) or short deletions in 
the consensus splice sites of introns 6 and 7. These 
data suggest that this gene, termed the survival motor 
neuron (SMN) gene, is an SMA-determining gene. 
Introduction 
Spinal muscular atrophies (SMAs) are characterized by 
degeneration of the anterior horn ceils of the spinal cord, 
leading to progressive symmetrical limb and trunk paraly- 
sis associated with muscular atrophy. SMA represents the 
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second most common fatal autosomat recessive disorder 
after cystic fibrosis (1 in 6000 newborns) (Roberts et al., 
1970; Pearn, 1973, 1978; Czeizel and Hamula, 1989). 
Childhood SMA is classically subdivided into three clinical 
groups on the basis of age of onset and clinical course 
(Munsat, 1991). The acute form of Werdnig-Hoffmann dis- 
ease (type I; Werdnig, 1894; Hoffmann, 1900) is character- 
ized by severe, generalized muscle weakness and hypoto- 
nia at birth or within the next 3 months. Death from 
respiratory failure usually occurs within the first 2 years. 
This disease may be distinguished from the intermediate 
(type II) and juvenile (type III or Kugelberg-Welander dis- 
ease; Kugelberg and Welander, 1956) forms. Type II chil- 
dren are able to sit, although they cannot stand or walk 
unaided, and survive beyond 4 years. Type III patients 
have proximal muscle weakness, starting after the age of 
2. The underlying biochemical defect(s) remains unknown. 
By means of linkage analysis, we and others have shown 
that all three forms of SMA map to chromosome 5q11.2- 
q13.3 (Brzustowicz et al., 1990; Melki et al., 1990a, 1990b, 
1993; Gilliam et al., 1990; Sheth et al., 1991; Lien et al., 
1991 ; Morrisson et al., 1992; Soares et al., 1993; Clermont 
et al., 1994). Various yeast artificial chromosome (YAC) 
contigs of the 5q13 region spanning the disease locus 
have been constructed and the presence of low copy re- 
peats in this region demonstrated (Kleyn et al., 1993; Fran- 
cis et al., 1993; Melki et al., 1994). Allele segregation was 
analyzed at the closest genetic loci, detected by markers 
derived from the YAC contig (C212, C272, and C161), in 
201 SMA families. These markers revealed either two 
(C212 and C272) or three (C161) loci in the 5q13 region. 
Inherited or de novo deletions were observed in nine unre- 
lated SMA patients. Moreover, deletions were strongly 
suggested in at least 18% of SMA type I patients by the 
observation of marked heterozygosity deficiency for the 
loci studied. These results indicated that deletion events 
are statistically associated with the severe form of SMA 
(type I). Recently, similar results were obtained with the 
Agl-CA marker in type I SMA individuals (DiDonato et 
al., 1994). Studying all polymorphic DNA markers derived 
from the YAC contig, we observed that the smallest re- 
arrangement occured within a region bordered by loci de- 
tected by C161 and C212-C272 and entirely contained in 
a 1.2 Mb YAC clone, 903D1 (Melki et al., 1994). 
In this report, we present the characterization of the 
small (140kb) nested critical SMA region by a combination 
of genetic and physical mapping in SMA patients. This 
region suggested a precise location for the SMA gene 
and, therefore, a limited region within which to search for 
candidate genes. We identified a duplicated gene in the 
5q13 region, one of which, the survival motor neuron 
(SMN) gene, was located within the critical region. This 
gene was lacking in 213 of 229 (93%) or interrupted in 13 
of 229 (5.6%) SMA patients. In patients in which the SMN 
gene was neither lacking nor interrupted, the presence of 
deleterious mutations provided strong evidence that this 
gene is an SMA-determining gene. 
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Figure 1. Physical Map of the SMA Locus 
(a) Organization of the YAC contig spanning 
the SMA region. DNA and microsatellite mark- 
ers are indicated above and below the genomic 
map, respectively. Above the He3 marker are 
indicated in parenthesis the sizes of the Hindlll 
restriction fragments detected bythis marker. 
The genomic ut sites for the enzymes Sill (Sf), 
Eagl (E), and Sacll (S) are shown. The positions 
of the restriction sites and markers provided 
evidence for an inverted duplication of an ele- 
ment that was divided into E TM and E TM ac- 
cording to location. Arrows indicate the limits of 
T~ the genomic rearrangements observed in SMA 
L-51 
L-I~ patients. The positions of the NAIP genes with 
L-5 
L-13 respect to CBCD541 and TBCD541 (SMN) genes 
are indicated. Abbreviations: Cent, centro- 
mere; Tel, telomere. Hatched bars indicate chi- 
meric YAC clones. 
(b) Phage contig spanning the SMN gene in the critical region of the 
E TM.  DNA and microsatellite markers a eindicated above the g nomic 
map. Genomic ut sites forthe enzymes Hindlll (H), EcoRI (Ec), Sfil(Sf), 
Sacll (S), and Eagl (E) are shown. Arrows indicate the limits of genomic 
rearrangements observed in SMA patients. The orientation ofthe SMN 
gene is indicated. 
(c) Length variation of Sill, Eagl, and Sacll restriction fragments from 
control and SMA individuals identified with probe 132SEll. PFGE of 
digested DNA from controls (lanes 1-4) and SMA (lanes 5-8) using 
Eagl, Sacll, and Sill was probed with the clone 132SE11. PFGE analy- 
sis revealed a high degree of restriction fragment variability using both 
enzymes insensitive (Sill) and sensitive (Eagl and Sacll) to sequence- 
specific methylation. 
Results 
Pulsed Field Gel Electrophoresis Analysis Reveals 
a Large Inverted Duplication and a Complex 
Genomic Organization of the 5q13 Region 
in Normal Chromosomes 
A YAC contig of the 5q13 region spanning the disease 
locus has been constructed. The haplotypes of YACs at 
the polymorphic loci detected by microsatellite markers 
C212, C272, C171, C161 (Melki et al., 1994), CMS1 (Kleyn 
et al., 1993), and 2AE9 (Francis et al., 1993) were com- 
pared with that of the human donor whose genomic DNA 
was used to construct the Centre d'Etudes du Polymor- 
phisme Humain (CEPH) YAC libraries. Agl-CA and CA TT1 
primers are within the sequence of markers C272 and 
C161, respectively (DiDonato et al., 1994; Burghes et al., 
1994). All the subloci detected by these markers on each 
chromosome of the human donor were present in this YAC 
contig and confirmed the extension of the YAC contig over 
the entire SMA region (Melki et al., 1994; Figure la). Con- 
sequently, the resulting contig was larger than those re- 
ported by the other groups (Kleyn et al., 1993; Francis et 
al., 1993; McLean et al., 1994; DiDonato et al., 1994). 
To elucidate the physical organization of the SMA candi- 
date region, we performed long-range restriction mapping 
of the YAC contig using pulsed field gel electrophoresis 
(PFGE), and the restriction enzymes Sacll, Sill, and Eagl 
were used to digest the YACs containing the telomeric 
loci detected by markers C212, C272, C171, and C161 
(YAC clone 595Cl l) ;  the centromeric loci detected by 
these markers (YAC clones 121B8, 759A3, and 278G7); 
or both loci (YAC clones 903D1 and 920C9). X phage librar- 
ies of YACs 595C11,121B8, and 903D1 were constructed, 
and subclones p322, 132SE 11, He3, 131 xb4, and pl 1 M1 
were isolated from phages containing microsatellite mark- 
ers C212, C272, C161, AFM157xd10 (Melki et al., 1994), 
and CMS1 (Kleyn et al., 1993), respectively. These were 
used as probes for PFGE analysis. The restriction map of 
the region (Figure 1 a) shows that probes 132SE11, pl 1 ml ,  
and p322 revealed two loci and probe He3 revealed four 
loci on the YAC contig, whereas probe 131xb4 revealed 
several loci on 5ql 3 and 5p (data not shown). The positions 
of the restriction sites and markers provided evidence for 
a large inverted duplication of an element of approximately 
500 kb, termed E Tet and E TM for the telomeric and centro- 
meric elements, respectively (Figure l a). Interestingly, 
PFGE analysis of the region revealed a high degree of 
variability in both SMA and control individuals. This vari- 
ability could be due to a variable number of repeated se- 
quences in the general population and hampered our abil- 
ity to distinguish E TM from E cen and to recognize abnormal 
restriction fragments in SMA patients (Figure tc).  
Southern Blot Analysis Enables the E TM and E cen 
of the Duplication to Be Distinguished 
DNA from the YAC clones of the contig and from the SMA 
patients and controls Was digested with restriction en- 
zymes Sacl, Kpnl, Mspl, Pstl, Pvull, EcoRI, Hindlil, Bglll, 
and Xbal for Southern blotting and hybridized with clones 
132SEll, p11m1, He3,131xb4, and p322 as probes. Only 
one probe, He3, derived from phage containing microsa- 
tellite marker C161, detected a difference between the two 
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Figure 2. Genetic and Physical Mapping of 
Genomic Rearrangements in SMA Individuals 
(a) Southern blot analysis Of Hindlll-digested 
DNA from YAC clones and the human donor 
probed with He3. The genomic probe He3, de- 
rived from the phage containing marker C161, 
detected three restriction fragments of 12 kb, 
11 kb, and 3.7 kb in the human donor whose 
genomic DNA was used to construct he CEPH 
YAC libraries. Southern blot analysis from 
Hindlll-digested DNA of YAC clones and the 
human donor (lane 1), probed with He3, de- 
tected the 12 kb fragment in YAC clones 754H5 
(lane 2) and 759A3 (lane 3),indicating that this 
fragment was specific for the most proximal 
locus detected by this probe. The presence of 
the 11 kb fragment in YAC clones 903D1 (lane 
7) and 595C11 (lane 6) indicated that this frag- 
ment was specific for the E TM. The detection of 
the 3.7 kb fragment in the nonoverlapping YAC 
clones containing E cen (278G7, lane 4; 121B8, 
lane 5) or B TM (595Cll, lane 6) indicated that 
this fragment corresponded to two different loci 
in each element. 
(b) Southern blot analysis of Hindlll-digested DNA from controls (lanes 1-3)and SMA patients (lanes 4-9) probed with He3. The 11 kb telomeric- 
specific Hindlll fragment, detected by probe He3, was absent in consanguineous type I patients (lane 4-6) and, in one patient, also involved the 
3.7 kb Hindlll fragment (lane 6). By contrast, the 11 kb telomeric-specific fragment was present in consanguineous type Ill patients (lane 7-9). 
(c) Allele segregation analysis at loci detected by marker C272 in consanguineous SMA patients. The figure shows family studies based on 
microsatellite DNA marker C272. The SMA patients belonged to type I (families 1,2, and 3) or type III (families 4, 5, and 6). Consanguineous type 
I SMA patients had one single PCR amplification product, as compared with 0 of 59 controls (Melki et al., 1994). By contrast, consanguineous 
type III SMA patients had two C272 amplification products, inherited from both parents, indicating homozygosity by descent, at each locus detected 
by marker C272. Abbreviations: F, father; M, mother; A, affected. Dots indicate allelic fragments. 
(d) Gene dosage analysis of the 5q13 region with the 132SE11 probe in consanguineous SMA patients and controls. Total human DNA from SMA 
patients or controls was digested with Hindlll restriction enzyme for Southern blotting. Filters were consecutively hybridized with 132SEll (a) and 
an internal anonymous control probe 122P1 (b). Gene dosage was determined by densitometric scanning of the hybridization signals. A marked 
decrease in 132SE11 band intensity was observed in consanguineous type I SMA patients (408/0, 14%, and 20% in lanes 1-3, respectively) as 
compared with the controls (115%, 85%, and 100% in lanes 4-6, respectively). By contrast, no gene dosage effect was observed in consanguineous 
type III patients, indicating the absence of deletions involving the locus detected by 132SEll (120%, 92%, and 88% in lanes 7-9, respectively). 
duplicated elements in control individuals. Upon analysis 
of total human DNA, probe He3 detected three Hindlll re- 
striction fragments of 12 kb, 11 kb, and 3.7 kb, respectively 
(Figure 2a). The 12 kb Hindlll restriction fragment was 
present in YAC clones 754H5 and 759A3, indicating that 
this fragment corresponded to the most proximal locus of 
the E cen (Figure 2a). The 11 kb Hindlll f ragment was pres- 
ent in YAC clones 595C11,903D1, and 920C9, indicating 
that this fragment corresponded to a single locus of the 
E Te~ (Figure 2a). Finally, the 3.7 kb Hindlll fragment was 
present in the nonoverlapping YAC clones 595C l l  and 
121B8, containing E Tel and E ce", respectively, indicating 
that this fragment corresponded to two different loci (Fig- 
ure 2a). Similar results were obtained using restriction en- 
zymes Sact and Kpnl (data not shown). The three restric- 
tion fragments detected by He3 were observed in the 
monochromosomal  hybrid H HW105 (Carlock et al., 1985) 
and in 30 unrelated healthy individuals, confirming that 
these fragments were not due to allelic polymorphisms 
(data not shown). These results al lowed E Te~ to be distin- 
guished from E cen in both controls and SMA patients. 
The Combined Use of Genetic and Physical 
Mapping to Identify Genomic Rearrangements 
in the E Te~ of SMA Patients 
Among 201 SMA patients previously analyzed with mark- 
ers C212, C272, and C161, nine carried large-scale dele- 
tions of a single mutant chromosome and were selected 
in the present study (Melki et al., 1994). In addition, 29 
inbred SMA families of various ethnic origins were studied 
at the most closely flanking polymorphic loci (D5S629, 
D5S637, D5S351, D5S435, D5S1364, D5S1365, and 
D5S1370; data not shown but available on request). Ho- 
mozygosity at these loci in affected children born to con- 
sanguineous parents provided evidence for identical mu- 
tations on both mutant chromosomes. We investigated 
further 12 of 13 type I, 1 of 6 type II, and 9 of 10 type Ill 
SMA patients who were homozygous by descent. 
The genomic DNA of the nine patients harboring large- 
scale deletions of a single mutant chromosome and the 
21 type I and III consanguineous patients showing homo- 
zygosity by descent was digested with Hindlll for Southern 
blotting and hybridized with probe He3 (Figure 2b). The 
11 kb telomeric-specific fragment was absent in 11 of 12 
consanguineous type I patients. In 2 of 11 patients, the 
deletion also involved the 3.7 kb He3 fragment. By con- 
trast, the 11 kb telomeric-specific fragment was absent in 
only 1 of 9 consanguineous type III patients. In 4 of 9 
patients harboring large-scale deletions of a single mutant 
chromosome, the 11 kb Hindlll fragment was absent. Of 
particular interest was the absence of the 11 kb telomeric- 
specific fragment in the patient harboring a deletion of one 
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Figure 3. Nucleotide Sequence of SMN cDNA 
The predicted amino acid sequence ncoded by the SMN cDNA is 
shown below the DNA sequence, assuming that ranslation begins at 
the first in-frame methionine ofthe ORF. Triangles indicate the intron- 
exon junctions. Arrowheads indicate the position of the single base 
differences observed in exons 7 and 8, between the SMN and the 
centromeric genes. 
of the two loci detected by markers C212 and C272 (Melki 
et al., 1994), indicating the presence of a deletion involving 
the telomeric loci detected by markers C212, C272, and 
He3. Taken together, these observations provided evi- 
dence for genomic rearrangements of the E T" in SMA pa- 
tients. In addition, as all but one of the consanguineous 
type III patients were not deleted for this locus, these data 
supported the location of the SMA gene centromeric to 
the telomeric-specific He3 locus (Figure la). 
To define the centromeric boundaries of the genomic 
rearrangements in SMA, we analyzed the allele segrega- 
tion at loci detected by microsatellite marker C272 in the 
21 type I and III consanguineous SMA patients showing 
homozygosity by descent (Figure 2c). All consanguineous 
type I SMA patients had only one single polymerase chain 
reaction (PCR) amplification product, a feature that was 
not observed in 59 controls (Melki et al., 1994). This reduc- 
tion in the number of C272 loci was due to the deletion 
of one of the two loci detected by C272, as indicated by 
the marked decrease in gene dosage with probe 132SE11, 
which maps close to this marker (Figure 2d). By contrast, 
8 of 9 consanguineous type III SMA patients had two C272 
amplification products, inherited from both parents, indi- 
cating homozygosity at each locus detected by marker 
C272 (Figure 2c). Thus, no reduction in the number of 
C272 loci was observed in all but one of the consanguine- 
ous type Ill patients. Similarly, no gene dosage effect was 
detectable with probe 132SEll, indicating the absence of 
deletions involving these loci in consanguineous type III 
patients (Figure 2d). Our results suggested that the dis- 
ease-causing gene is distal to the telomeric locus detected 
by C272 (Figure la). 
These studies placed the SMA gene within the E Te', be- 
tween the telomeric locus detected by marker C272 and 
the 11 kb telomeric-specific locus detected by He3 (Figure 
la). Based on long-range restriction mapping of the YAC 
contig using PFGE, this critical region is entirely contained 
in a terminal 140 kb SaclI-pYAC fragment of YAC clone 
903D1 (or a 150 kb SaclI-pYAC fragment of YAC clone 
920C9; Figure la). 
Construction of a Phage Contig Spanning the 
Critical Region of the ET": Identification and 
Characterization of a Candidate Gene 
Phage clones containing markers C212, C272, C171, and 
C161 were isolated from the ~. phage library constructed 
from YAC clone 595C11 and used as starting points for 
bidirectional walking. A phage contig of the E TM encom- 
passing markers C212, C272, and C171 was constructed 
based on the restriction map of the phage clones (Figure 
lb). The probe 132SEll, derived from the phage con- 
taining marker C272, gave positive hybridization signals 
with hamster DNA, indicating the presence of interspe- 
cies-conserved sequences. The screening of a ;~gtl0 hu- 
man fetal brain cDNA library with probe 132SEll resulted 
in the selection of seven overlapping ;~ clones spanning 
1.6 kb. Sequence analysis of the clones revealed an 882 
bp open reading frame (ORF) and a 580 bp noncoding 
region (Figure 3). A 1.5 kb cDNA clone (BCD541) con- 
tained the entire coding sequence and most of the 3' non- 
coding region. The 3' end of the cDNA along with its 
poly(A) ÷ tail was obtained by PCR amplification of a lym- 
phoblastoid cell line cDNA library (see Experimental Pro- 
cedures). Northern blot analysis of poly(A) + RNA from vari- 
ous tissues, including heart, brain, liver, muscle, lung, 
kidney, and pancreas, revealed the presence of a widely 
expressed 1.7 kb transcript (Figure 4a). This gene is also 
expressed in spinal cord (data not shown). The ORF en- 
codes a putative protein of 294 amino acids with a pre- 
dicted molecular mass of approximately 32 kDa (Figure 
3). An homology search using the FASTA and BLAST net- 
works failed to detect any homology at either the nucleo- 
tide or the amino acid levels. Anticipating the results pre- 
sented below, this candidate gene was called the survival 
motor neuron (SMN) gene. 
Evidence for a Duplication of the SMN Gene 
in the 5q13 Region 
The BCD541 cDNA clone was used as a probe for South- 
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the hybridization signals. A significant decrease in BCD541 cDNA band intensity was observed 
compared with the controls (lanes 6 and 7). 
Figure 4. RNA Analysis of BCD541 Gene 
Transcripts in Controls and SMA Individuals 
(a) The BCD541 cDNA, hybridized to a North- 
ern blot containing 2 p_g of poly(A) ÷ RNA per 
lane from heart (lane 1), brain (lane 2), placenta 
(lane 3), lung (lane 4), liver (lane 5), skeletal 
muscle (lane 6), kidney (lane 7), and pancreas 
(lane 8) (Clonetech) revealed the presence of a 
widely expressed 1.7 kb transcript in all tissues 
tested. Filters were consecutively hybridized 
with BCD541 cDNA and an internal control 
probe ~,-actin. 
(b) Northern blot analysis of SMN in SMA pa- 
tients and controls. Northern blot analysis of 
poly(A)- RNA isolated from lymphoblastoid cell 
lines of controls (lanes 6 and 7) and SMA pa- 
tients (lanes 1-5) hybridized with the BCD541 
cDNA. SMA patients belonged to type I (lanes 
1-4) or type III (lane 5). Filters were consecu- 
tively hybridized with BCD541 cDNA and an 
internal control probe ~-actin. Gene dosage 
was determined by densitometric scanning of
in 2 of 4 type I SMA patients (lanes 1 and 4) 
(c) RT-PCR analysis of BCD541 transcripts in controls and SMA patients. RT-PCR amplification using oligonucleotides located in exons 6 and 
8 (541C618 and 541C1040) from lymphoblastoid cell lines in SMA patients (lanes 1-11) and controls was performed (lanes 12-19). All patients 
presented here, except one (patient SA, carrying both the SMN and centromeric genes; lane 7), were lacking telomeric exons 7 and 8. All controls 
but two (carrying only the SMN gene; lanes 13 and 16) carried both the SMN and the centromeric genes. Electrophoresis on 2% Seaplaque 
agarose of RT-PCR amplification products revealed two bands corresponding to differential splicing of exon 7 in the BCD541 transcripts. Controls 
carrying only the SMN gene expressed only the 0.42 kb RT-PCR products containing exon 7 (lanes 13 and 16). Controls carrying both e 
centromeric and the SMN genes• expressed both the 0.42 kb RT-PCR products and the 0.36 kb RT-PCR products lacking exon 7 (lanes 12, 14- 
15, and 17-19). RT-PCR analysis showed that in controls the 0.36 kb RT-PCR products were far less abundant han the 0.42 kb RT-PCR products. 
In SMA patients lacking the SMN gene on both mutant chromosomes, both species were observed, and the amount of the 0.36 kb RT-PCR 
products was comparable or even more abundant han that of the 0.42 kb RT-PCR products (lanes 1-11). In patient SA (lane 7), carrying both 
the centromeric gene(s) and the SMN gene with a 7 bp deletion in the 3' splice acceptor site of intron 6, the amount of the 0.36 kb RT-PCR 
products was more abundant han that of the 0.42 kb RT-PCR products, demonstrating the deleterious effect of the deletion on the processing 
of the mutant SMN gene. 
(d) Schematic representation f the differential splicing of exon 7 of the BCD541 transcripts in controls and SMA patients. Line 1, genomic 
organization of the centromeric (CBCD541) and the SMN genes (TBCD541); line 2, splicing patterns of BCD541 transcripts in controls carrying both 
genes (CBCD541 and TBCD541); line 3, splicing patterns of transcripts of the TBCD541 (SMN) gene in controls carrying the SMN gene only; line 
4, splicing patterns of the BCD541 transcripts in SMA patients carrying only the CBCD541 gene; line 5, abnormal splicing of the mutant SMN gene 
transcripts (TBCD541) in patient SA carrying a deletion in the 3' splice acceptor site of intron 6. 
ern blot and PFGE analyses of YACs spanning the disease 
locus. Specific hybridization with nonoverlapping YACs 
containing only E TM (YAC clones 759A3, 121 B8, and 278G7) 
or only E TM (YAC clone 595C l l )  provided evidence for 
the duplication of the SMN gene (Figure la). Each gene 
encompassed approximately 20 kb and displayed an iden- 
tical restriction pattern (data not shown). Hybridization ex- 
periments with probes BCD541 and p322 that closely 
f lanked the Sacll, Sill, and Eagl sites of each element gave 
evidence for head-to-head orientation of the two genes 
(Figure 1 a). 
To search for differences between the two genes, the 
organization of the SMN gene was characterized and com- 
pared with that of the centromeric counterpart (see Experi- 
mental Procedures). Genomic sequence analysis re- 
vealed that the SMN gene is composed of eight exons 
(Figure 3). Starting from either the centromeric or telo- 
meric gene locus (in YAC clones 121B8 and 595Cl l ,  re- 
spectively), PCR amplif ication and sequence analysis of 
each exon and its f lanking regions revealed five discrepan- 
cies between the centromeric and the SMN genes. These 
were a synonymous mutation in exon 7 (codon 280; TTC, 
telomeric; Tr-I-, centromeric; Figure 3), a 3' noncoding re- 
gion change in exon 8 (nucleotide 1155; TGG, telomeric; 
TGA, centromeric; Figure 3), and three other single base 
substitutions in the sixth and seventh introns (data not 
shown). The presence of both versions of each exon (exon 
7 and 8) on a YAC clone containing both gene loci (YAC 
clone 920C9) and in the monochromosomal hybrid HHW105 
(Carlock et al., 1985) demonstrated that these substitu- 
tions are neither allelic nor due to polymorphisms (Figure 
5). Band shifts on single strand conformation polymor- 
phism (SSCP) analysis of exons 7 and 8 PCR-amplified 
products al lowed the SMN (also termed TBCD541) and cen- 
tromeric (CBCD541) genes in both controls and SMA pa- 
tients to be readily distinguished. All (100%) unrelated 
controls tested (n = 246) carried the SMN gene, as shown 
by SSCP analysis of exons 7 and 8. The majority (235 of 
246; 95.5%) also carried the centromeric CBCD541, but 
11 of 246 (4.4%) lacked CBCD541 (Figure 5). 
Absence of the SMN (TBCD541) Gene 
in SMA Patients 
SSCP analysis of amplified exons 7 and 8 was carried out 
in 229 SMA patients. Of these, 103 belonged to type I, 91 
to type II, and 35 to type III. A total of 213 of 229 SMA 
patients (93%) lacked the SMN exons 7 and 8 on both 
mutant chromosomes as compared with 0 of 246 controls 
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Figure 5. SSCPAnalysisofAmplifiedExons7and8fromYACClones, 
the Monochromosomal Hybrid HHW105, Controls, and SMA Patients 
Band shifts on SSCP analysis of PCR-amplified products of exons 7 (a) 
and 8 (b) allowed the SMN and centromeric genes to be distinguished. 
Bands indicated by closed arrowheads are present in YAC clone 
595C11 containing only the E TM, indicating that these bands are spe- 
cific to the telomeric exons 7 and8. The presence of different bands 
in YAC clone 121 B8 containing only the E c8° (indicated by open arrow- 
heads) showed that these fragments are specific to centromeric exons 
7 and 8. Both conformations are present in YAC 920C9 and the 
monochromosomal hybrid HHWl05, indicating that both genes are 
present and that they are not allelic. Control individuals are shown in 
lanes 21-30. The majority of these carried both telomeric and centro- 
meric exons. Controls in lanes 21 and 22 carried only the telomeric 
exons 7 and 8. Lanes 1-20 contained amplified exons 7 and 8 from 
SMA patients. The majority of these carried only centromeric exons 
7 and 8 (lanes 1-14). Patients in lanes 15 (HU), 16 (SA), and 17 (BI) 
carried both telomeric and centromeric exons 7 and 8. The abnormal 
band size seen in patient SA (lane 16) corresponds to the 7 bp deletion 
in the sixth intron of the 3' splice acceptor site. Patients in la e  18- 
20 lacked the telomeric exon 7 on both mutant chromosomes, but 
carried the telomeric exon 8, indicating an interruption of the SMN 
gene between exons 7 and 8 on both mutant chromosomes. Lane 20 
shows the SSCP analysis in the consanguineous type III patient in 
whom the exon 7-8 PCR product contained a centromeric exon 7 but
a telomeric exon 8.
(0%; Figure 5). Interestingly, 13 of 229 SMA patients 
(5.6%) lacked the SMN exon 7 on both mutant chromo- 
somes but retained the SMN exon 8, as compared with 0 
of 246 controls (0%; Figure 5). Further, in one of these, 
a consanguineous type III patient, amplification of exon 7 
to exon 8 resulted in a product in which sequence analysis 
showed that exon 7 was centromeric but that exon 8 was 
derived from the telomeric gene (Figure 5). As both exonic 
and intronic sequences were completely normal and no 
abnormal restriction fragment was present on Southern 
blot analysis (data not shown), this suggested that a gene 
conversion event may have occurred. Finally, only 3 of 
229 (1.3%) SMA patients carried the SMN exons 7 and 8 
as compared with all the controls (100%; Figure 5). SSCP 
analysis of am plified exon 7 was carried out in 127 parents 
of SMA patients. All parents tested carried at least one 
copy of the SMN gene (100%; data not shown but available 
on request). 
These results showed that the SMN gene is either absent 
or truncated in 98.6% of SMA patients. In addition, the 
observation of patients lacking the SMN exon 7 but not 
the SMN exon 8 (13 of 229) supported the view that the 
gene defect is centromeric to SMN exon 8 (Figure lb). 
Thus, the critical region is included in a 20 kb region be- 
tween the C272 telomeric sublocus and SMN exon 8, partly 
containing the SMN gene, which can be regarded, there- 
fore, as a determining ene for SMA (Figure lb). 
Intragenic Mutations of the SMN Gene 
To demonstrate that the SMN gene (rBCD541) is indeed 
a determining ene for SMA, we searched for mutations 
in the three SMA patients whose SMN gene showed no 
rearrangements. PCR amplification of exon 7 and its flank- 
ing regions revealed, in addition to the normal-sized PCR 
product, a smaller fragment in patient SA (Figure 5a). Di- 
rect sequence analysis of the smaller fragment showed 
a 7 bp deletion in the 3' splice acceptor site of SMN intron 
6 (Figure 6). Sequence analysis of the normal-sized PCR 
product detected the sequence specific to the centromeric 
exon 7 but not that of the SMN exon 7 (data not shown). 
These results demonstrated that patient SA carried an 
intronic deletion of the SMN gene on one mutant allele 
and lacked the SMN exon 7 on the other mutant allele. 
This intronic deletion was inherited from the mother, and, 
in contrast with that of her affected child, the allelic frag- 
ment was specific to the SMN gene, confirming that the 
unaffected mother is, indeed, heterozygous for the muta- 
tion (data not shown). In patient BI, a 4 bp deletion was 
found in the 5' consensus splice donor site of SMN intron 
7 (Figure 6). Sequence analysis of the nondeleted amplifi- 
cation product recognized the centromeric exon 7, but 
not the SMN exon 7, suggesting that the other mutant 
chromosome lacked the SMN exon 7 (data not shown). 
These two mutations were absent in 246 control individu- 
als. Such mutations have been found in other genes and 
typically abolish or disrupt splicing (Bottema et al., 1990; 
Murru et al., 1991). Finally, patient HU was heterozygous 
for a point mutation at codon 272 (TAT--*TG'I'), changing 
a tyrosine into a cysteine in the protein (Figure 6). This 
mutation was absent in 100 normal chromosomes, ruling 
out rare polymorphisms. 
RNA Analysis Revealed Differential Splicing of Exon 
7 in the Centromeric (CBCD541) and SMN Genes 
Eight unrelated controls and 10 of 11 SMA patients lacking 
the SMN gene on both mutant chromosomes but carrying 
the CBCD541 gene (type I SMA, 7 patients; type II SMA, 
1 patient; type III SMA, 3 patients) were selected for North- 
ern blot analysis of their lymphoblastoid cell line poly(A) + 
RNAs using a full-length BCD541 cDNA probe and a 
13-actin cDNA probe as the internal control. Using the 
BCD541 cDNA, we detected a single 1.7 kb mRNA in the 
controls and the patients. Interestingly, however, the rela- 
tive amount of the specific mRNA was markedly reduced 
in 4 of 7 SMA type I patients as compared with controls 
(Figure 4b). As all 10 patients lacked the SMN gene on 
both mutant chromosomes but carried at least one copy of 
the CBCD541 gene, this result suggested that the CBCD541 
gene is transcribed. 
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Figure 6. Intragenic Mutations in Patients SA, 
BI, and HU Carrying the Telomeric Gene 
Mutant sequences of patients SA, BI, and HU 
(above) and control sequences (below) are 
shown. Arrows indicate the position of dele- 
tions (patient SA and patient BI) or the point 
mutation (patient HU). Triangles indicate the 
intron-exon junctions and solid lines the se- 
quences of exons 7 (patient SA and BI) and 6 
(patient HU). 
Amplification and sequence analysis of exons 6-8 from 
reverse transcribed RNAs confirmed that the SMN tran- 
scripts were absent and that the CBCD541 transcripts were 
solely present in patients lacking the SMN gene on both 
mutant chromosomes, while control individuals expressed 
both RNA transcripts (CBCD541 and SMN; Figure 4d). 
These studies also revealed that the centromeric tran- 
scripts, but not the SMN gene transcripts, may normally 
undergo alternative splicing of exon 7 to produce tran- 
scripts lacking this exon. This was shown by the observa- 
tion that controls lacking the CBCD541 gene on both chro- 
mosomes expressed only the full-length RNA while 
controls carrying both the cent romeric and the SMN genes 
expressed full-length and truncated RNA (Figures 4c and 
4d). These results suggested that the truncated RNA tran- 
scripts are specific for the centromeric gene (Figure 4d). 
In patient SA, who carried a 7 bp deletion in the 3' splice 
acceptor site of SMN intron 6, SMN exon 7 was shown to 
be absent in SMN transcript (Figures 4c and 4d). These 
results showed the deleterious effect of this intronic dele- 
tion on SMN transcript splicing. 
Finally, reverse transcription-PCR (RT-PCR) analysis 
of control RNAs showed that the truncated CBCD541 tran- 
scripts were far less abundant han full-length RNA tran- 
scripts (Figure 4c). By contrast, the amount of truncated 
CBCD541 transcripts was comparable or even more abun- 
dant than that of the full-length RNA in SMA patients (Fig- 
ure 4c). These results suggested that the amount of full- 
length and truncated RNA differed between controls and 
SMA patients. 
Discussion 
We and other groups (Brzustowicz et al., 1990; Melki et 
al., 1990a, 1990b, 1993; Gilliam et al., 1990; Sheth et al., 
1991 ; Lien et al., 1991 ; Morrisson et al., 1992; Soares et 
al., 1993; Clermont et al., 1994) have previously localized 
the SMA locus to chromosome 5q13, a region character- 
ized by the presence of low copy repeat elements (Kleyn 
et al., 1993; Francis et al., 1993; Melki et al., 1994). The 
construction of a YAC contig encompassing the SMA lo- 
cus enabled the detailed physical mapping of this region 
and led to the identification of a large inverted duplication 
of a 500 kb element within this region (E cen and ETel). Physi- 
cal mapping studies by PFGE on genomic DNA from nor- 
mal individuals revealed a high degree of variability of this 
region that could be explained by the variable number 
of repeated sequences in the general population. It was, 
however, possible using Southern blot analysis to distin- 
guish E Te~ from E ce° using probe He3, which detected dis- 
tinct restriction fragments corresponding to specific loci 
on the E ce" and ET~L 
In this report, we present the identification and charac- 
terization of a gene, which we have called the SMN gene, 
that is duplicated within the 5q13 region and that we be- 
lieve is a determining ene for SMA. The genomic organi- 
zation of both the telomeric (SMN or TBCD541) and the 
centromeric (CBCD541) genes was identical, suggesting 
a recent duplication event. Five discrepancies enabled the 
SMN and the centromeric (CBCD541) genes to be distin- 
guished. Two of these, in exons 7 and 8, were readily 
distinguished by SSCP analysis and were used to show 
the presence or absence of these genes. Analysis of a 
control population showed that the SMN gene was present 
in all individuals while the CBCD541 gene was present in 
95.5%. This indicated that the telomeric one was the an- 
cestral gene (SMN). 
Northern blot analysis of RNA from a range of tissues, 
including spinal cord, showed that this gene was widely 
expressed and resulted in a 1.7 kb mRNA transcript. The 
ORF encoded a putative protein of 294 amino acids with 
a predicted molecular mass of 32 kDa. No homology was 
found at the nucleotide or amino acid levels with any pre- 
viously identified protein, suggesting that this gene en- 
codes a novel protein of unknown function. The presence 
of interspecies-conserved sequences within the SMN 
gene will enable the isolation of homologous equences 
and will enable the identification of functionally conserved 
domains within the SMN protein. Sequence analysis of 
reverse-transcribed RNAs from controls showed that both 
genes are expressed, although it is unclear whether both 
are translated into functional proteins. In addition, the cen- 
tromeric gene (CBCD541), specifically, was shown to un- 
dergo alternative splicing of exon 7, resulting in a trun- 
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cated transcript lacking this exon and a putative protein 
with a different C-terminal end. This truncated transcript 
was less abundant han the full-length transcript in normal 
individuals carrying both centromeric and telomeric genes. 
These results enabled the SMN and the CBCD541 genes 
to be distinguished at the RNA level. 
We have recently reported the presence of large-scale 
deletions encompassing the disease locus on one mutant 
chromosome in nine unrelated SMA patients (Melki et al., 
1994). These deletions allowed us to assign the SMA locus 
to a 1.2 Mb critical region flanked by the microsatellite 
marker C161. Moreover, deletions were strongly sug- 
gested in at least 18% of SMA type I patients by the obser- 
vation of a reduced number of C212 and C272 subloci. 
These results indicated that deletion events are statisti- 
cally associated with the severe form of SMA (type I). Re- 
cently, DiDonato et al. (1994) also demonstrated a highly 
significant association between Agl-CA alleles and type 
I SMA, confirming our previous results, as Agl-CA primers 
are a subset of the C272 sequence. As a result of the high 
degree of variability of this region in the general popula- 
tion, we were unable to recognize abnormal restriction 
fragments or to narrow the SMA critical region further by 
PFGE analysis in SMA patients. Nevertheless, the com- 
bined genetic and physical analysis of consanguineous 
patients carrying identical mutations on both mutant chro- 
mosomes and of patients with large-scale deletions on 
one mutant chromosome placed the SMA gene between 
the telomeric subloci detected by markers C272 and He3, 
in a 140 kb fragment of E Te~. 
Among the candidate genes identified within the 5q13 
region, one, the SMN gene, was located between markers 
C272 and He3. Specific sequence variations between the 
centromeric (CBCD541) and SMN genes showed that in 
93% of patients (213 of 229), the SMN gene was absent 
on both mutant chromosomes. Moreover, the interruption 
of the SMN gene between exons 7 and 8 in 13 of 229 
SMA patients (5.6o) reduced the critical region to a 20 kb 
fragment, between the telomeric loci detected by marker 
C272 and SMN exon 8. Mutation analysis in the three pa- 
tients retaining the SMN gene identified deleterious muta- 
tions on one mutant chromosome in all three cases and 
showed that the SMNgene was absent on the other mutant 
chromosome in two of these. The fact that either intragenic 
mutations or lack of the SMN gene resulted in an SMA 
phenotype, while the absence of the CBCD541 gene had no 
apparent phenotypic effect, strongly suggested a critical 
function for SMN as compared with CBCD541. 
Northern blot analysis in patients lacking SMN genes 
on both mutant chromosomes but carrying at least one 
copy of the CBCD541 gene showed a marked decrease of 
RNA in only 4 of 7 type I patients. On the other hand, RT- 
PCR analysis of lymphoblastoid cell lines from patients 
lacking both SMN genes showed the presence of °BCD541 
gene transcripts only. In addition, the proportion of the 
truncated transcripts specific to the CBCD541 gene, rela- 
tive to the full-length species, was increased in SMA pa- 
tients, whereas in controls the full-length RNA represented 
the major species. As the truncated transcripts may result 
in a putative protein with a different C-terminal end, the 
relevance of these observations to the disease phenotype 
requires further investigation. 
Taken together, our data suggest that the SMN gene is 
an SMA-determining ene. Unfortunately, lack of polymor- 
phism at the SMN locus hampered our ability to estimate 
the actual frequency of de novo rearrangements, pre- 
viously reported in SMA (Melki et al., 1994). On the other 
hand, no phenotype-genotype correlation between the 
gene defect and the type of SMA was observed, as the 
SMN gene was absent or truncated in 98.6% of the pa- 
tients independent of the type of SMA. We have previously 
shown that deletion events are, statistically, associated 
with the severe form (type I) of SMA (Melki et al., 1994). 
Consanguineous patient analysis, using markers flanking 
the SMN gene (C272 and He3), showed that deletions are 
more frequent and larger in type I than in type III patients. 
Indeed, 11 of 12 type I consanguineous patients had dele- 
tion involving the telomeric loci detected by markers C272 
and He3, while 0 of 9 type III consanguineous patients 
had deletion involving both loci. One could hypothesize 
that regulatory elements or gene(s) mapping close to the 
SMN gene, as the one reported by Roy et al. (1995 [this 
issue of Cell]), may be involved in the large genomic re- 
arrangements present in type I SMA, thus altering the clini- 
cal phenotype of the patients. In keeping with this, we 
were able by PFGE analysis and PCR amplification to 
localize the neuronal apoptosis inhibitory protein (NAIP) 
gene and its truncated forms with respect to the SMN gene 
using primers 1926-1933 and 1258-1343 for the 5' and 
the 3' ends of the NAIP gene, respectively (Roy et al., 
1995). Both PCR amplification and PFGE analysis on our 
YAC and phage contigs provided evidence that the NAIP 
gene was at least duplicated (Figure la). Moreover, the 
telomeric version of the NAIP gene was distal to the 3' 
end of the SMN gene with the following order: C272- 
5'-SMN-3'--3'-NAIP-5'--Tel (data not shown but available 
on request): Although the telomeric NAIP gene was con- 
tained in the SMA critical region defined by the telomeric 
loci detected by markers C272 and He3, the NAIP gene 
was distal to the SMN exon 8 (Figure la). Consequently, 
the NAIP gene mapped outside the nested critical SMA 
region defined by C272 and SMN exon 8. As this gene is 
very close to the SMN gene, it might be involved in the 
large genomic deletions present in type I but not in type 
III SMA patients. Further investigations are required to 
confirm the involvement of both a determining gene and 
a modifying gene in SMA. 
On the othe r hand, the absence of the SMN gene without 
gene dosage effect in type III may be accounted for by 
gene conversion events changing the SMN into the 
CBCD541 gene, thus resulting in an increased number of 
CBCD541 copies. Thishypothesis is supported by the ob- 
servation of the type III patient in whom a single exon 
7-8 amplification product contained a centromeric exon 
7 linked to a telomerically derived exon 8. A similar mecha- 
nism had been previously suggested in steroid 21-hydrox- 
ylase deficiency (Higashi et al., 1988). Under this hypothe- 
sis, the number of copies of the SMN gene would be 
reduced in all types of SMA. Thus, consanguineous SMA 
patients harboring identical mutant haplotypes would be 
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expected  to carry two CBCD541 genes  in type I (one on 
each chromosome)  and four  CBCD541 genes  in type III 
(two on each chromosome) .  Interest ingly,  the absence  of 
both SMN and CBCD541 genes  was not observed  in our  
series. Such a genotype  wou ld  be expected  to result in 
an ext remely  severe  form of  SMA or in a nonv iab le  fetus. 
This s ituation may be s imi lar  to that prev ious ly  reported in 
(~-thalassemia (Orkin, 1987). Assuming  that  the CBCD541 
gene is t rans lated into, at least, a part ial ly funct ional  pro- 
tein, the d i f ferent  phenotypes  of  SMAs  wou ld  depend on 
the number  of CBCD541 genes  on each chromosome.  
Our  abil ity to detect  98 .6% of  SMA pat ients by analys is  
of  exon 7 of  the SMN gene will revolut ion ize cl inical and 
precl inical  test ing for this d isorder  and will great ly  faci l i tate 
genet ic  counse l ing  by e l iminat ing the need for  complex  
l inkage analysis.  Further, it will ex tend the opt ion of prena-  
tal d iagnos is  to fami l ies in which af fected indiv iduals are 
not avai lab le  to establ ish genet ic  phase.  
A l though the exact  nature of  the genet ic  mechan isms 
result ing in SMAs  remains  to be clarif ied, this s tudy pro- 
v ides important  c lues to the unravel ing of this complex  
puzz le  and forms a base f rom which to exp lore  the molecu-  
lar biology, b iochemistry ,  and cell b io logy of  this devastat -  
ing d isease.  Fur thermore,  this work  will contr ibute to the 
fundamental  understanding of  the survival of motor neurons. 
Experimental Procedures 
YAC Library Screening 
YAC libraries from CEPH were screened by PCR with microsatellite 
markers C212, C272, C171, CMS1, and C161 according to the three- 
dimensional procedure (Green and Olson, 1990). YAC genotypes were 
established by electrophoresis of am plification products on denaturing 
polyacrylamide gels (Hazan et al., 1992). YAC size was estimated by 
PFGE. 
Construction of Phage Libraries from YAC Clones 121B8, 
595Cll ,  and 903D1 
Total yeast DNA from YAC clone 595C11, containing the telomeric 
loci detected by C212, C272, and C161; from YAC clone 121B8, con- 
taining the centromeric loci detected by the same markers; or from 
YAC clone 903D1, containing both loci, was purified and partially di- 
gested with restriction enzyme Sau3A. DNA in the 12-23 kb size range 
was excised after 0.5% Seaplaque GTG agarose gel electrophoresis 
and precipitated with ethanol after 13-agarase digestion. After partial 
fill-in of the Sau3A site, DNA was subcloned at the partially filled Xhol 
site of bacteriophage FIXII (Stratagene). Phage clones containing the 
microsatellite DNA markers C212 (L-51), C272 (L-51 and L-132), C171 
(L-5 and L-13), C161 (595B1), CMS1 (L-11), and AFM157xdlO (L-131) 
were digested with the restriction enzyme EcoRI or Hindlll or with both 
and subcloned into the Pucl 8 plasmid vector. Subclones from phages 
containing markers C212 (p322), C272 (132SEll), C161 (He3), 
AFM157xdlO (131xb4), and CMS1 (p11M1) were used as probes. 
PFGE Analysis 
High molecular weight DNA was isolated in agarose plugs from Ep- 
stein-Barr virus-transformed lymphoblastoid cell lines established 
from controls and patients or from YAC clones as described previously 
(Herrmann et al., 1987). Plugs were rinsed twice for 30 min each in 
10-20 vol of TE buffer. The plugs were equilibrated for 30 rain at 4°C 
with 0.3 ml of the appropriate restriction enzyme buffer containing 0.1 
mg/ml BSA (Pharmacia). Excess buffer was removed, and the plugs 
were incubated at the appropriate temperature for 16 hr with 40 U of 
restriction enzyme per reaction. DNA was digested with the restriction 
enzymes Eagl, Sill, and Sacll. Double digestions of DNA from YAC 
clones with SfiI-Eagl, SfiI-Sacll, and EagI-Sacll were also performed. 
Separation of DNA fragments was achieved using a CHEF-Ill-DR 
PFGE apparatus (Bio-Rad). Fragments of 50-1200 kb were separated 
by electrophoresis through 1% Seakem agarose at 200 V for 24 hr at 
14°C in 0.5 x TBE running buffer using a 30-70 s ramping pulse time. 
The separation of fragments of 5-100 kb was performed by electropho- 
resis at 200 V for 19 hr at 14°C in 0.Sx TBE buffer using a 5-20 s 
ramping pulse time. After treatment with 0.25 N HCI for 20 min, pulsed 
field gels were blotted onto Hybond N ÷ nylon membranes (Amersham) 
in 0.4 N NaOH, 0.4 M NaCI for 20 hr. Probes were successively hybrid- 
ized to the same filters to ensure accurate data. 
Southern Blot and Dinucleotide Repeat 
Polymorphism Analysis 
DNA was extracted from YAC DNA clones or peripheral blood teuko- 
cytes or lymphoblastoid cell lines. DNA was digested with the restric- 
tion enzyme Sacl, Kpnl, EcoRI, Hindlll, Bglll, Xbal, Pvull, Xmnl, Rsal, 
Pstl, or BamHI, separated by electrophoresis on a 0.8% agarose gel 
for Southern blotting, and hybridized with radioactively labeled probes 
(Sambrook et al., 1989). For genotyping using marker C272 
(D5F150S1 and D5F150S2), amplification conditions were as folIows: 
denaturation at 94°C, annealing at 55°C, and extension at 72°C for 
1 rain each for 30 cycles (Melki et ai., 1994). 
cDNA Screening and Characterization 
Recombinant clones (2 x 108) of a Xgtl0 human fetal brain cDNA 
library were plated according to the instructions of the manufacturer 
(Clonetech). Prehybridization and hybridization with labeled probes 
were carried out in a solution containing 5x  SSEP, 1% SDS, and 
5 x Denhardt's olution with 100 ~g/ml denaturated sheared human 
placental DNA (Sigma) for t6 hr at 65°C. The filters were washed in 
0.1 x SSEP, 0.1% SDS at 65°C and autoradiographed for 24 hr. The 
DNA of positive clones was purified, digested with EcoRI, and sub- 
cloned in M13mp18 bacteriophage. Single-stranded DNAs were se- 
quenced using the DyeDeoxy terminator cycle sequencing kit protocol 
supplied by Applied Biosystems and were analyzed on an ABI model 
373A DNA automated sequencer. To obtain the 3' end of the cDNA 
along with its poly(A) ÷ tail, we performed PCR amplification of a lym- 
phoblastoid cell line cDNA library using a primer complementary to 
the 3' end of the BCD541 cDNA and a primer specific to the vector 
arms of the cDNA library as previously described (Fournier et al., 1994). 
Specific PCR products were sequenced directly with both pdmers. 
Homology searches using the FASTA and BLAST systems through 
the CITI2 French network (Dessen et al., 1990) were performed at 
either the nucleotide or the amino acid levei. 
Genomic Sequence Analyses of the CBCD541 and SMN Genes 
DNA from phage clones containing the SMN gene (L-132, L-5, and 
L-13) was digested with either Hindlll or EcoRI or with both and sub- 
cloned into the Puc18 plasmid vector. DNA sequencing reactions were 
performed on double-stranded plasmid DNA with oligonucleotides de- 
rived from the cDNA sequence. Genomic DNA sequences were com- 
pared with the cDNA sequence, and oligonucleotide~ derived from 
exon flanking regions were designed to amplify and directly to se- 
quence each exon of the CBCD541 and SMN genes. 
Control and SMA patient DNA was sequenced directly using the 
amplification products of each exon. PCR products were purified by 
polyacrylamide gel electrophoresis and subjected to a second round 
of PCR amplification. When the size of the amplification products dif- 
fered, each band was separated by polyacrylamide gel electrophoresis 
before reamplification and sequencing using both primers. In cases 
in which sequence analysis revealed heterozygosity for mutations, 
PCR amplification products were cloned into the pBluescript SK(+) 
vector (Stratagene) to confirm nucleotide substitutions. 
SSCP Analysis 
For SSCP analysis, DNA from peripheral leukocytes (200 ng) was 
amplified by PCR using unlabeled primers (20 ~M) in 25 p.t of amplifica- 
tion mixture containing 200 I~M dNTPs, 1 U of Taq polymerase (GIBCO 
BRL), and 0.1 ~1 of [~-33P]dCTP (10 mCi/ml; New England Nuclear). 
Amplified DNA was mixed with an equal volume of formamide loading 
dye (95% formamide, 20 mM EDTA, 0.05% bromophenol blue, 0.05% 
xylene cyanol). The samples (5 p.I) were denatured for 10 min at 95°C 
and loaded onto a polyacrylamide gel (Hydrolink MED, Bioprobe) and 
electrophoresed at 4°C for 18-24 hr at 4 W. Gels were transferred 
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onto 3MM Whatman paper, dried, and autoradiographed using Kodak 
X-OMAT films for 24-48 hr. To amplify genomic DNA containing diver- 
gent exon 7 sequences, we used oligonucleotides R111 (5'-AGACTAT- 
CAACTTAATTTCTGATCA-39 and 541 C770 (5'-TAAG GAATGTGAGC- 
ACCTTCCTTC-3'). To amplify genomic DNA containing divergent 
exon 8 sequences, we used oligonucleotides 541C960 (5'-GTAATAAC- 
CAAATGCAATGTGAA-3') and 54 l c l  120 (5'-CTACAACACCCTTCTC- 
ACAG-3'). 
RNA Procedures 
Poly(A) ÷ RNA from lymphoblastoid cell lines of controls and SMA pa- 
tients was isolated using the QuickPrep mRNA purification kit (Phar- 
macia) and electrophoresed on a 1.5% Seakem agarose gel containing 
10 mM methylmercury hydroxide in a 5 mM tetraborate buffer, 10 mM 
sodium sulfate, 1 mM EDTA, and 50 mM boric acid (pH 8.2), transferred 
to a positively charged membrane in 2Ox SSC, and baked for 2 hr 
at 80°C. After hybridization, the membranes were washed to a final 
stringency of 0.1 x SSEP, 0.10/o SDS at 65°C for 10 rain. Autoradiogra- 
phy was at -80°C with intensifying screens and using Kodak XAR 
films for 2-10 days. The ~-actin cDNA was used as an internal control 
probe, and the autoradiographs were scanned at 600 nm using a com- 
puterized densitometer (Hoeffer Scientific Instruments). A Northern 
blot of poly(A)* RNA from several human tissues was purchased from 
Clonetech. 
First-strand synthesis of cDNA from poly(A) ÷ RNA was carried out 
using random hexanucleotide primers and AMV reverse transcriptase 
(Promega). The single-stranded cDNAs were consequently amplified 
by PCR using 2 pmol of forward (541C618, 5'-CTCCCATATGTCCA- 
GATTCTCTTG-3') and reverse (541C1040, 5'-ACTGCCTCACCACCG- 
TGCTGG-3') primers in a final volume of 20 Id containing 1 U of Taq 
polymerase (Cetus). Amplification conditions were as follows: denatur- 
ation at 94°C, annealing at 55°C, and extension at 72°C for 1 rain 
each for 30 cycles. The PCR products were separated, excised after 
polyacrylamide gel electrophoresis, and eluted in 100 pl of TE buffer. 
The diluted fragments were reamplified with the same primers prior 
to direct sequencing with both primers using the DyeDeoxy terminator 
cycle sequencing kit protocol (Applied Biosystems). 
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